




Name	Sheehyun Kim	
Current Position	Clinical Assistant Professor	
Country	Republic of Korea	
Major Field	Hemato-oncology, Bioinformatics	

Educational Background

2020 – Present: Seoul National University College of Medicine, Ph.D. Candidate
 2012 – 2016: Seoul National University, School of Medicine, M.D.
 2006 – 2008: KAIST Department of Bio and Brain Engineering, M.S.
 2003 – 2006: KAIST Department of Bio and Brain Engineering, B.S.

Professional Experience

2022 – Present: Seoul National University Hospital, Clinical Assistant Professor (Genomic Medicine)
 2021 – 2022: Seoul National University Hospital, Clinical Fellow (Genomic Medicine)
 2020 – 2021: Seoul National University Hospital, Clinical Fellow (Hemato-oncology)
 2017 – 2020: Seoul National University Hospital, Resident (Internal Medicine)
 2016 – 2017: Seoul National University Hospital, Intern

Other Experience and Professional Memberships

2021- : Korean Society of Medical Genetics and Genomics
 2020- : Korean Society of Medical Oncology
 2020- : Korean Cancer Study Group

Main Scientific Publications

1. Kim S*, Kim S*, Kim SH, et al. Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patients. *Transl Lung Cancer Res* 2023;12(6):1185-1196. DOI: 10.21037/tlcr-22-912.
2. Kim S*, Cha Y*, Lim Y, et al. Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis. *Int J Cancer* 2023;153(3):571-583. DOI: 10.1002/ijc.34558.



-
3. Cha Y*, **Kim S***, Han SW. Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers. *Cancer Res Treat* 2023. DOI: 10.4143/crt.2023.446.
 4. Kim MJ*, **Kim S***, Chae SW, et al. Prevalence and founder effect of DRC1 exon 1-4 deletion in Korean patients with primary ciliary dyskinesia. *J Hum Genet* 2023. DOI: 10.1038/s10038-023-01122-8.
 5. **Kim S***, Lim Y*, Kang JK, et al. Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment. *Br J Cancer* 2022;127(5):898-907. DOI: 10.1038/s41416-022-01837-z.
 6. Lim Y*, **Kim S***, Kang JK*, et al. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR. *Sci Rep* 2021;11(1):16333. DOI: 10.1038/s41598-021-95345-4.
 7. **Kim S**, Yoon SS, Hong J, et al. Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk. *Anticancer Res* 2020;40(5):2917-2924. DOI: 10.21873/anticancer.14269.
 8. Ju YS*, Kim JI*, **Kim S***, et al. Extensive genomic and transcriptional diversity identified through massively parallel DNA and RNA sequencing of eighteen Korean individuals. *Nat Genet* 2011;43(8):745-52. DOI: 10.1038/ng.872.
-